抗2型糖尿病药物研究新进展  

Progress in New Drugs for Treatment of Type 2 Diabetes Mellitus

作　　者：万星驿 李玲[1] 

机构地区：[1]昆明医科大学生物医学工程研究中心,昆明650500

出　　处：《医学综述》2014年第22期4133-4135,共3页Medical Recapitulate

基　　金：云南省应用基础研究计划重点项目(2006C009Z)

摘　　要：糖尿病主要表现为高血糖及微血管并发症,主要分为1型和2型糖尿病,其中2型糖尿病占糖尿病患者的90%-95%。近年来糖尿病药物的研究取得了较大进展,出现了很多新型的抗糖尿病药物,如二肽基肽酶4抑制剂、胰高血糖素样肽1类似物、钠-葡萄糖协同转运蛋白2抑制剂和白细胞介素1受体拮抗剂等。该文就抗2型糖尿病药物研究新进展予以综述。Diabetes mellitus is characterized by high blood glucose level accompanied with various microvascular complications,and are categorized into type 1 diabetes and type 2 diabetes. The percentage of type 2 diabetes is up to 90% to 95%. Antidiabetic drug research has made great progress in recent years,such as dipeptidyl peptidase-4 inhibitor,glucagon-like peptide-1 analogue,sodium-glucose co-transporter-2inhibitors,interleukin-1 receptor antagonist and so on. Here is to make a review of the recent progress in antidiabetic drugs for type 2 diabetes.

关 键 词：2型糖尿病 抗糖尿病药物 胰高血糖素样肽1类似物 二肽基肽酶4抑制剂 钠-葡萄糖协同转运蛋白2抑制剂 白细胞介素1受体拮抗剂 

分 类 号：R977.15[医药卫生—药品]